Generex works on early diabetes test for children:
This article was originally published in Clinica
Executive Summary
Generex Biotechnology's subsidiary, Antigen Express, is developing a diagnostic kit for the early detection and screening of type 1 diabetes in young children. In a collaboration with two European diabetes centres, the company is to begin in vitro studies to identify the immune mechanisms that lead to the destruction of insulin-producing cells in the pancreas and to the onset of type 1 diabetes. The studies will focus on the role that lymphocytes play in a series of pancreatic antigens. Toronto, Canada-based Generex said that characterising these lymphocytes could lead to the development of a better screening parameter for those at risk of developing the disease, earlier diagnosis and possible intervention.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.